Comprehensive Overview of Congestive Heart Failure and Pharmacological Management Strategies

Comprehensive Overview of Congestive Heart Failure and Pharmacological Management Strategies

• 1.
  Congestive Heart Failure andthe Drugs Used in Its Management Mr. SATENDRA PRADHAN Assistant Professor Department of Pharmacology COP, SVITS, Bilaspur Ms. MANISHA SAHU Assistant Professor Department of Pharmacology SCCP, Rajnandgaon
• 2.
  OVERVIEW What Is CongestiveHeart Failure? Result of: Impaired ventricular filling (diastolic) or ejection (systolic) of blood Leads to: Pulmonary & systemic venous congestion + reduced tissue perfusion Compensation: RAAS & sympathetic activation — helpful acutely, harmful chronically Congestive Heart Failure (CHF) is a clinical syndrome in which the heart is unable to pump blood at a rate sufficient to meet the metabolic demands of the tissues, or can do so only at elevated filling pressures. Reduced Cardiac Output Heart fails to eject sufficient blood per minute Fluid Retention Activation of RAAS & sympathetic system → Na+/water retention Ventricular Remodeling Compensatory hypertrophy & dilation worsen function over time
• 3.
  M ECHANISM OFDISEASE Pathophysiology
• 4.
  CLASSIFICATIO N OFCHF HFrEF vs. HFpEF HFrEF Heart Failure with Reduced Ejection Fraction EF ≤ 40% Systolic dysfunction — impaired contractility Dilated, thin-walled ventricle Most evidence-based drug therapy targets this group Common causes: MI, dilated cardiomyopathy HFpEF Heart Failure with Preserved Ejection Fraction EF ≥ 50% Diastolic dysfunction — impaired relaxation/filling Thick, stiff, hypertrophied ventricle Management mainly symptomatic + comorbidity control Common causes: hypertension, aging, diabetes
• 5.
  CLINICAL PRESENTATION Signs &Symptoms of CHF Left-Sided / Pulmonary Congestion Dyspnea on exertion, orthopnea, PND Fatigue & exercise intolerance Bilateral basal crepitations Cough, frothy sputum Right-Sided / Systemic Congestion Bilateral pedal / pitting edema Raised JVP, hepatomegaly Ascites in advanced disease Weight gain from fluid retention
• 6.
  TREATM ENT STRATEGY Goalsof Pharmacotherapy in CHF Relieve Symptoms Reduce congestion, edema & dyspnea for immediate comfort Improve Quality of Life Increase exercise tolerance & reduce hospitalizations Slow Disease Progression Prevent / reverse ventricular remodeling Reduce Mortality Block harmful neurohormonal (RAAS/sympathetic) activation Modern GDMT (Guideline-Directed Medical Therapy) combines four pillars — RAAS blockade, beta-blockade, MRA, and SGLT2 inhibition — for maximal mortality benefit.
• 7.
  DRUG CLASSES Classification ofDrugs Used in CHF PDE = Phosphodiesterase ACE = Angiotensin-Converting Enzyme
• 8.
  DRUG CLASSES Classification ofDrugs Used in CHF 1 Diuretics Loop, Thiazide 2 ACE Inhibitors / ARBs Enalapril, Losartan 3 Beta Blockers Bisoprolol, Carvedilol 4 Aldosterone Antagonists (MRA) Spironolactone, Eplerenone 5 ARNI (Angiotensin Receptor–Neprilysin Inhibitor) Sacubitril + Valsartan 6 SGLT2 Inhibitors Dapagliflozin, Empagliflozin 7 Cardiac Glycosides Digoxin 8 Vasodilators Hydralazine + Nitrates
• 9.
  CLASS 1 ·DIURETICS Diuretics — Mechanism of Action Loop & thiazide diuretics reduce preload by promoting salt & water excretion Block Na⁺-K⁺-2Cl⁻ symporter (thick ascending limb) [Loop] or Na⁺-Cl⁻ cotransporter (DCT) [Thiazide] → ↓ Reabsorption of Na⁺, Cl⁻, K⁺ → ↑ Osmotic gradient → ↑ Water excretion (diuresis) → ↓ Plasma volume → ↓ Venous return (preload) → Relief of pulmonary & systemic congestion Net effect: reduced circulating volume lowers ventricular filling pressures, relieving dyspnea and peripheral edema — the fastest-acting symptomatic therapy in CHF.
• 10.
  CLASS 1 ·DIURETICS Diuretics — Uses & Side Effects Furosemide, Bumetanide (Loop) · Hydrochlorothiazide, Metolazone (Thiazide) Therapeutic Uses First-line for volume overload / congestion Rapid relief of pulmonary edema (loop, IV in acute HF) Reduce peripheral & pulmonary edema Improve exercise tolerance by decreasing preload Adjunct to RAAS/BB therapy — no proven mortality benefit alone Side Effects Hypokalemia, hypomagnesemia Hypotension & pre-renal azotemia Ototoxicity (high-dose loop diuretics) Hyperuricemia → gout flares Metabolic alkalosis; hyperglycemia (thiazides)
• 11.
  CLASS 2 ·RAAS BLOCKADE ACE Inhibitors — Mechanism of Action Interrupt the renin-angiotensin-aldosterone system at the conversion step Inhibit ACE (Angiotensin- Converting Enzyme) → ↓ Angiotensin II formation + ↑ Bradykinin → ↓ Vasoconstriction ↓ Aldosterone secretion → ↓ Afterload ↓ Preload (Na⁺/H₂O retention ↓) → ↓ Cardiac remodeling ↑ Survival By lowering angiotensin II, ACE inhibitors reduce both afterload (vasodilation) and preload (less aldosterone-driven fluid retention), and blunt the maladaptive remodeling that drives HF progression — first-line, mortality-reducing therapy in HFrEF.
• 12.
  CLASS 2 ·RAAS BLOCKADE ACE Inhibitors & ARBs — Uses & Side Effects Enalapril, Lisinopril, Ramipril (ACEI) · Losartan, Valsartan, Candesartan (ARB, if ACEI-intolerant) Therapeutic Uses First-line in all stages of HFrEF (NYHA I–IV) Reduce mortality & hospitalization Slow / reverse ventricular remodeling Also used in hypertension & diabetic nephropathy ARBs substituted when ACEI causes cough/angioedema Side Effects Dry, persistent cough (bradykinin-mediated) Hyperkalemia Angioedema (rare but serious) First-dose hypotension Acute kidney injury, especially with renal artery stenosis
• 13.
  CLASS 3 ·NEUROHORM ONA L BLOCKADE Beta Blockers — Mechanism of Action Counteract chronic sympathetic overactivation in CHF Competitively block β1-adrenergic receptors in myocardium → ↓ Heart rate & ↓ Contractility (acute) → ↓ Renin release ↓ Myocardial O₂ demand → ↓ Chronic sympathetic toxicity on myocytes → Reverse remodeling ↑ EF over months Started at low dose in stable, euvolemic patients and up-titrated slowly — initial negative inotropy is offset by long-term reduction in catecholamine-driven myocardial damage, improving survival.
• 14.
  CLASS 3 ·NEUROHORM ONA L BLOCKADE Beta Blockers — Uses & Side Effects Bisoprolol, Carvedilol, Metoprolol succinate (evidence-based in HFrEF) Therapeutic Uses Standard of care in stable, chronic HFrEF Reduce mortality & sudden cardiac death Improve symptoms & EF with long-term use Also control heart rate in AFib coexisting with HF Carvedilol adds α₁-blockade → additional vasodilation Side Effects Bradycardia & heart block Hypotension, dizziness, fatigue Bronchospasm (non-selective agents) May precipitate acute decompensation if started in unstable HF Cold extremities, masking of hypoglycemia
• 15.
  CLASS 4 ·ALDOSTERONE ANTAGONIST S Mineralocorticoid Receptor Antagonists — MOA Block the end-organ effects of aldosterone directly Competitively block aldosterone receptors in distal nephron → ↓ Na⁺/H₂O reabsorption ↑ K⁺ retention → Mild diuretic + K⁺-sparing effect → ↓ Myocardial & vascular fibrosis (direct tissue effect) → ↓ Remodeling ↑ Survival Beyond their weak diuretic action, MRAs block aldosterone's direct pro-fibrotic effect on the heart and vasculature — this tissue-level action is the main reason they reduce mortality in HFrEF.
• 16.
  CLASS 4 ·ALDOSTERONE ANTAGONIST S MRAs — Uses & Side Effects Spironolactone, Eplerenone Therapeutic Uses Added to ACEI/ARB + BB in NYHA II–IV HFrEF Reduce mortality & hospitalization (RALES, EMPHASIS- HF) Used post-MI with LV dysfunction Also used for resistant hypertension Eplerenone preferred if antiandrogenic effects unwanted Side Effects Hyperkalemia (monitor K⁺ & renal function) Gynecomastia & menstrual irregularities (spironolactone) Renal impairment, especially with ACEI/ARB combo Rare: metabolic acidosis Requires regular electrolyte monitoring
• 17.
  CLASS 5 ·ARNI (Angi ote ns i n Receptor –N epril ys i n Inhibi tor) Sacubitril/Valsartan — Mechanism of Action Dual action: neprilysin inhibition + angiotensin receptor blockade Sacubitril inhibits neprilysin (degrades natriuretic peptides) → ↑ ANP, BNP levels → natriuresis & vasodilation → Valsartan blocks AT1 receptors (as in ARBs) → Combined ↓ preload, ↓ afterload, ↓ fibrosis → Superior mortality reduction vs ACEI (PARADIGM-HF) ARNI combines the beneficial natriuretic-peptide pathway (protective, but degraded by neprilysin) with angiotensin blockade — now preferred over ACE inhibitors in eligible HFrEF patients.
• 18.
  CLASS 5 ·ARNI ARNI — Uses & Side Effects Sacubitril + Valsartan (fixed-dose combination) Therapeutic Uses Replaces ACEI/ARB in symptomatic HFrEF Reduces cardiovascular death & HF hospitalization Recommended by current guidelines as preferred RAAS agent Improves symptoms and functional class Not started same-day as ACEI — 36-hour washout required Side Effects Hypotension (more common than ACEI) Hyperkalemia Angioedema (lower risk than ACEI, still possible) Renal function decline Contraindicated with concurrent ACEI use
• 19.
  CLASS 6 ·NEWEST PILLAR OF GDM T SGLT2 Inhibitors — Mechanism, Uses & Side Effects Inhibit SGLT2 in proximal renal tubule → ↓ Glucose & Na⁺ reabsorption → Osmotic diuresis + natriuresis → ↓ Preload & improved cardiac metabolism → ↓ HF hospitalization (regardless of diabetes status) Uses — Dapagliflozin, Empagliflozin Approved for HFrEF AND HFpEF, with or without diabetes Reduce HF hospitalization & CV death Added on top of standard 4-pillar GDMT Additional renal-protective benefit Side Effects Genital mycotic infections (esp. in women) Urinary tract infections Volume depletion / hypotension Rare: euglycemic diabetic ketoacidosis
• 20.
  CLASS 7 ·CARDIAC GLYCOSIDES Digoxin — Mechanism, Uses & Side Effects Inhibits Na⁺/K⁺- ATPase pump (myocyte membrane) → ↑ Intracellular Na⁺ → ↓ Na⁺-Ca²⁺ exchange → ↑ Intracellular Ca²⁺ → ↑ Contractility (+ ve inotropy) → ↑ Vagal tone → ↓ AV conduction / HR Uses Symptomatic HFrEF, especially with coexisting AFib Controls ventricular rate in AFib + HF Reduces hospitalizations — NO mortality benefit Reserved for symptoms persisting on GDMT Side Effects — Narrow Therapeutic Index GI: nausea, vomiting, anorexia Visual disturbance — yellow-green halos (xanthopsia) Arrhythmias (esp. with hypokalemia) Toxicity potentiated by hypokalemia, renal impairment
• 21.
  SUMMARY The Four Pillarsof GDMT in HFrEF 1 ARNI / ACEI / ARB RAAS blockade 2 Beta Blocker Neurohormonal blockade 3 MRA Aldosterone blockade 4 SGLT2 Inhibitor Metabolic & diuretic effect Added as needed: Diuretics — for congestion / volume overload (symptom control, not mortality) Digoxin — for persistent symptoms or rate control in AFib Hydralazine + Nitrates — in select / ACEI-intolerant patients Goal of therapy: relieve symptoms today, and modify neurohormonal disease biology for tomorrow.